Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 05 01 2018
pubmed: 11 4 2018
medline: 7 1 2020
entrez: 11 4 2018
Statut: ppublish

Résumé

Complement is thought to play a role in immunoglobulin A nephropathy (IgAN), though the activating mechanisms are unknown. This study focused on the gene expression of CD46 and CD55, two key molecules for regulating C3 convertase activity of lectin and alternative complement pathways at a cellular level. The transcriptional expression in peripheral white blood cells (WBCs) of CD46 and CD55 was investigated in 157 patients enrolled by the Validation of the Oxford Classification of IgAN group, looking for correlations with clinical and pathology features and estimated glomerular filtration rate (eGFR) modifications from renal biopsy to sampling. Patients had a previous median follow-up of 6.4 (interquartile range 2.8-10.7) years and were divided into progressors and non-progressors according to the median value of their velocity of loss of renal function per year (-0.41 mL/min/1.73 m2/year). CD46 and CD55 messenger RNA (mRNA) expression in WBCs was not correlated with eGFR values or proteinuria at sampling. CD46 mRNA was significantly correlated with eGFR decline rate as a continuous outcome variable (P = 0.014). A significant difference was found in CD46 gene expression between progressors and non-progressors (P = 0.013). CD46 and CD55 mRNA levels were significantly correlated (P < 0.01), although no difference between progressors and non-progressors was found for CD55 mRNA values. The prediction of progression was increased when CD46 and CD55 mRNA expressions were added to clinical data at renal biopsy (eGFR, proteinuria and mean arterial blood pressure) and Oxford MEST-C (mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, presence of any crescents) score. Patients with progressive IgAN showed lower expression of mRNA encoding for the complement inhibitory protein CD46, which may implicate a defective regulation of C3 convertase with uncontrolled complement activation.

Sections du résumé

BACKGROUND
Complement is thought to play a role in immunoglobulin A nephropathy (IgAN), though the activating mechanisms are unknown. This study focused on the gene expression of CD46 and CD55, two key molecules for regulating C3 convertase activity of lectin and alternative complement pathways at a cellular level.
METHODS
The transcriptional expression in peripheral white blood cells (WBCs) of CD46 and CD55 was investigated in 157 patients enrolled by the Validation of the Oxford Classification of IgAN group, looking for correlations with clinical and pathology features and estimated glomerular filtration rate (eGFR) modifications from renal biopsy to sampling. Patients had a previous median follow-up of 6.4 (interquartile range 2.8-10.7) years and were divided into progressors and non-progressors according to the median value of their velocity of loss of renal function per year (-0.41 mL/min/1.73 m2/year).
RESULTS
CD46 and CD55 messenger RNA (mRNA) expression in WBCs was not correlated with eGFR values or proteinuria at sampling. CD46 mRNA was significantly correlated with eGFR decline rate as a continuous outcome variable (P = 0.014). A significant difference was found in CD46 gene expression between progressors and non-progressors (P = 0.013). CD46 and CD55 mRNA levels were significantly correlated (P < 0.01), although no difference between progressors and non-progressors was found for CD55 mRNA values. The prediction of progression was increased when CD46 and CD55 mRNA expressions were added to clinical data at renal biopsy (eGFR, proteinuria and mean arterial blood pressure) and Oxford MEST-C (mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, presence of any crescents) score.
CONCLUSIONS
Patients with progressive IgAN showed lower expression of mRNA encoding for the complement inhibitory protein CD46, which may implicate a defective regulation of C3 convertase with uncontrolled complement activation.

Identifiants

pubmed: 29635535
pii: 4964991
doi: 10.1093/ndt/gfy064
doi:

Substances chimiques

Biomarkers 0
CD46 protein, human 0
Complement Inactivating Agents 0
Membrane Cofactor Protein 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

587-596

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Auteurs

Rosanna Coppo (R)

Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.

Licia Peruzzi (L)

Department of Nephrology, Dialysis and Transplantation, Regina Margherita Hospital, Turin, Italy.

Elisa Loiacono (E)

Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.

Massimilano Bergallo (M)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Alexandra Krutova (A)

Department of Pediatrics, Regional Children's Clinical Hospital, Vladivostok, Russia.

Maria Luisa Russo (ML)

Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.

Enrico Cocchi (E)

Department of Nephrology, Dialysis and Transplantation, Regina Margherita Hospital, Turin, Italy.

Alessandro Amore (A)

Department of Nephrology, Dialysis and Transplantation, Regina Margherita Hospital, Turin, Italy.

Sigrid Lundberg (S)

Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.

Dita Maixnerova (D)

Department of Nephrology, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.

Vladimir Tesar (V)

Department of Nephrology, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.

Agnieszka Perkowska-Ptasińska (A)

Department of Transplantation Medicine and Nephrology, Medical University of Warsaw, Warsaw, Poland.

Magdalena Durlik (M)

Department of Transplantation Medicine and Nephrology, Medical University of Warsaw, Warsaw, Poland.

Dimitris Goumenos (D)

Department of Nephrology, University Hospital of Patras, Patras, Greece.

Miltiadis Gerolymos (M)

Department of Nephrology, University Hospital of Patras, Patras, Greece.

Kresimir Galesic (K)

Department of Nephrology, Dubrava University Hospital, Zagreb, Croatia.

Luka Toric (L)

Department of Nephrology, Dubrava University Hospital, Zagreb, Croatia.

Aikaterini Papagianni (A)

Department of Nephrology, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Maria Stangou (M)

Department of Nephrology, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Malgorzata Mizerska-Wasia Membek (M)

Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland.

Loreto Gesualdo (L)

Department of Nephrology, Emergency and Transplantation, University of Bari, Bari, Italy.

Eustacchio Montemurno (E)

Department of Nephrology, Emergency and Transplantation, University of Bari, Bari, Italy.

Luisa Benozzi (L)

Department of Nephrology, Borgomanero Hospital, Borgomanero, Italy.

Stefano Cusinato (S)

Department of Nephrology, Borgomanero Hospital, Borgomanero, Italy.

Tomasz Hryszko (T)

Department of Nephrology, Transplantation and Dialysis, Medical University of Bialystok, Bialystok, Poland.

Marian Klinger (M)

Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.

Dorota Kamińska (D)

Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.

Magdalena Krajewska (M)

Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH